New Treatments & Clinical Trials for Mantle Cell Lymphoma

Mantle cell lymphoma is a rare B-cell cancer that accounts for about 6% of non-Hodgkin lymphomas. Treatment typically combines chemotherapy with targeted drugs like ibrutinib, acalabrutinib, or zanubrutinib — BTK inhibitors that block a key growth signal in lymphoma cells. Many people achieve long remissions, though the disease often returns and requires new treatment lines.

What's actually going on in research

Trials are testing BTK inhibitors in earlier treatment lines, CAR T-cell therapy for relapsed disease, combinations of targeted drugs to avoid or delay chemotherapy, and maintenance strategies to extend remission. Researchers are also studying venetoclax, a BCL-2 inhibitor, in various combinations, and investigating minimal residual disease testing to guide treatment decisions.

What to know before you search

Eligibility often depends on number of prior treatments, extent of disease, blood counts, organ function, and sometimes TP53 mutation status or other molecular markers.

What types of trials are currently open

• Treatment trials — Testing new drug combinations for newly diagnosed or relapsed mantle cell lymphoma, often comparing BTK inhibitor regimens or adding venetoclax to standard treatment.
• CAR T-cell trials — Studies of engineered immune cells for people whose lymphoma has returned after standard treatments, or testing CAR T earlier in the disease.
• Maintenance trials — Testing whether continuing targeted drugs after chemotherapy or other initial treatment extends remission.
• Minimal residual disease trials — Using highly sensitive tests to detect tiny amounts of remaining cancer and guide decisions about continuing or stopping treatment.
• Quality of life studies — Following people to understand treatment side effects and how different approaches affect daily functioning.